Clinical Data Regenxbio’s Duchenne gene therapy clears phase 3 hurdle PharmaphorumRegenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche's Elevidys.Gene Therapy PlatformRead full story pharminent May 14, 2026 (Last updated: May 14, 2026) Pharmaphorum Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche’s Elevidys. Gene Therapy Platform Read full story Post navigation Previous: FDA hands BeOne, Taiho approvals for blood cancersNext: Degron adds $40M to series A, supporting immunology plans for molecular glue platform Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026